

March 8, 2017



Emmaus Life Sciences, Inc. to Present at Los Angeles Biomedical Research Institute's (LA BioMed) Innovation Showcase

TORRANCE, Calif., March 8, 2017 /PRNewswire/ -- Emmaus Life Sciences, Inc. announced today that Charles Stark, PharmD, Senior Vice President of Research and Development at Emmaus, will present at LA BioMed's 4th Annual Innovation Showcase on Thursday, March 9, 2017 in Manhattan Beach, CA. The Innovation Showcase brings together more than 300 participants from emerging life science companies and prestigious academic institutions across California to share knowledge and research about innovation in healthcare and discuss broader issues affecting the commercialization of new therapies.

"We are thrilled to be part of this important conversation about how organizations can continue to push forward novel solutions for the healthcare community and for patients," said Yutaka Niihara, MD, MPH, Chairman and Chief Executive Officer of Emmaus Life Sciences. "Countless patients across a variety of health conditions face high unmet need in their disease area, including sickle cell disease. It is critical that innovators share information across the industry to help fill these treatment gaps for patients."

LA BioMed is one of the country's leading nonprofit independent biomedical research institutes committed to finding practical, inexpensive solutions to real-world health problems through biomedical discovery, fostering the researchers of tomorrow, and promoting wellness in every community.

About Emmaus Life Sciences

Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The company's research on sickle cell disease was initiated by Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. For more information, please visit www.emmauslifesciences.com

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange

Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

For more information, contact:

Media:	Investors:
Jim Heins	Charles Butler
Senior Vice President	Senior Vice President
ICR Healthcare	ICR Healthcare
203-682-8251	415-430-2079
james.heins@icrinc.com	charles.butler@icrinc.com

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/emmaus-life-sciences-inc-to-present-at-los-angeles-biomedical-research-institutes-la-biomed-innovation-showcase-300420001.html>

SOURCE Emmaus Life Sciences, Inc.